Chatham House Report Concludes That Changing Hygiene Behaviors Can Lead to Better Health, for the Individual, the Wider Population, and the Economy
A lack of safe water, sanitation, and hygiene results not only in loss of dignity, safety, health, and education, but also economic potential. It is at the heart of “human capital,” not only for the current working generation, but for generations to come. However, the subject of hygiene has never been near the top of the political agenda, something that needs to change. More global efforts are needed to link hygiene with policy-influencing outcomes and establish return on investment (ROI) to drive policy change. While it is evident that progress is being made on an international basis, more still needs to be done.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005660/en/
Driving hygiene behaviors – essential elements of universal healthcare? (Photo: Business Wire)
This was the conclusion from an assembled group of 32 experts in their respective fields within health and health policy, many of them from low-and middle- income countries (LMICs), during a round table discussion organized and facilitated by Reckitt Global Health Institute (RGHI) and global think tank Chatham House. The discussions took place under Chatham House’s Commission for Universal Health, which is on its agenda until 2024, and jointly chaired by Helen Clark, the former prime minister of New Zealand, and Jakaya Kikwete, former president of Tanzania.
The group had been invited to discuss a variety of fundamental topics in the forum, Driving hygiene behaviors – essential elements of universal healthcare? The discussion took place under the Chatham House Rule. Participants are free to use the information received, but neither the identity nor the affiliation of the speaker(s), nor that of any other participant, may be revealed.
The panel of experts, which included politicians, policymakers, academics, physicians, behavior change experts, and others representing international charities and Ministries of Health concluded that investments are needed beyond research. Firstly, to build workable, scalable hygiene interventions, and secondly to build ‘customer demand’ from communities that will put pressure on governments to supply hygiene infrastructure.
Simon Sinclair, Executive Director of RGHI said: “Defining and quantifying the impact of hygiene measures, and learning how to implement them at scale, is imperative if hygiene is to be built successfully into national health systems.”
The group conceded that while hygiene will always be included within the WASH community, there is an increasingly urgent need to strengthen its presence to ensure areas such as menstrual and respiratory hygiene have a place within the conversation at national levels. Building a universal understanding of the wider scope of ‘hygiene’ is essential. Hygiene needs to be seen as an essential part of the connected universal healthcare agenda.
Developments in pharmaceutical options in the 20th through to 21st centuries have diluted the focus on basic hygiene as an intervention. The recent emergence of novel coronaviruses causing SARS, MERS, and COVID, and the lack of immediate pharmaceutical solutions, has brought hygiene sharply to the front of our minds once again. While the emphasis of conventional hygiene practices has been on fecal-oral diseases, the COVID pandemic has prompted a focus on respiratory hygiene practices beyond handwashing/keeping clean and relevant to transmission of acute respiratory infections (ARIs).
Simon Sinclair continued “Global community leaders have work ahead of them to expand access to good hygiene. The UN has set access to clean water, sanitation, and hygiene as a sustainable development goal, but sound sanitation services reached little more than half the world’s population as of 2020. While hygiene has long been seen as beneficial to health, it now needs to be understood as a connected part of the basic requirements in building national health systems.”
The investment case for making hygiene a critical element of universal health was a pivotal part of the conversation and a call to action going forward.
Notes to editors:
To download the report: RGHI website
RGHI, a not-for-profit foundation, was established in 2020 with a multi-year $25 million grant from Reckitt. RGHI is focused on plugging significant gaps in the health research space and improving access to information that will bridge epidemiology, public health, and behaviour change.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
To arrange an interview with RGHI / Chatham House
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carbios Hosts World’s First PET Biorecycling Summit with Bertrand Piccard, Initiator and Chairman of the Solar Impulse Foundation, as Keynote Speaker9.12.2022 08:45:00 EET | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005776/en/ Bertrand Piccard, Initiator and Chairman of the Solar Impulse Foundation, as Keynote Speaker at the First World PET Biorecycling Summit organised by Carbios Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, hosted the world’s first PET Biorecycling Summit from 7 to 8 December 2022 in Paris. The event attracted over 100 international participants from the scientific, academic, and industrial worlds to exchange on the advances in the field of biological recycling, and how to bring these innovations for a circular economy to market. The two-day conference gathered world-renowned scientists from various academic institutions to share their latest research on PET enzymatic depolymerization. Bertrand Piccard, Initiator and Chairman
Crash Bandicoot Returns in All-new Team Based, Four vs. Four, Competitive Showdown, Crash Team Rumble™9.12.2022 06:30:00 EET | Press release
Get ready to team up and throw down, because Crash and his friends (and foes) are back, and this time there will be some unexpected, fur-ocious competition! In development by the talented team at Toys for Bob who brought fans the acclaimed Crash Bandicoot™ 4: It’s About Time™, Crash Team Rumble ™ is an all-new 4v4, team-based online multiplayer video game set in Crash Bandicoot’s vibrant and zany universe. Published by Activision Publishing, Inc., Crash Team Rumble will release on PlayStation®5, PlayStation®4, Xbox® Series X/S and Xbox One® in 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005292/en/ Crash Team Rumble Gameplay Screenshot (Photo: Business Wire) In Crash Team Rumble , fans can play as Crash, Dingodile, and a host of other friends and frenemies, each of which has their own distinct power, personality, and playstyle, as they compete across wild and varied arenas in 4v4 team-based online multiplayer a
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer9.12.2022 02:00:00 EET | Press release
Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 70% of breast cancer tumors are considered HR positive and HER2 low or negative.1 For patients with HR positive, HER2 low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine the
TreviPay Acquires Apruve9.12.2022 01:45:00 EET | Press release
TreviPay, a leader in global B2B payments and invoicing solutions, today announced the signing of a definitive agreement to acquire payment platform Apruve. Apruve offers a robust suite of payment solutions for global enterprises that will complement and expand on TreviPay’s existing order-to-cash technology offerings, merchant invoicing solutions, and the geographical reach of TreviPay’s existing B2B networks. TreviPay has experienced unprecedented demand from global enterprise buyers and sellers resulting in 30% organic growth in 2022, and this acquisition furthers TreviPay's plans to expand its order-to-cash technology offerings and B2B payment network. This acquisition builds on TreviPay’s recent purchase of Baton Financial Services. “TreviPay provides payment and invoicing solutions for a number of leading manufacturers and OEMs; the acquisition of Apruve will accelerate our advancement in the technology manufacturing vertical and expand our geographic reach into key Asian markets
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy9.12.2022 00:05:00 EET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabometyx® (cabozantinib) in combination with atezolizumab (Tecentriq®) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy. Howard Mayer, M.D., Executive Vice President, Head of Research and Development at Ipsen, said: “The results from the CONTACT-01 clinical trial have shown the challenge of treating NSCLC patients after prior lines of treatment have failed. While the findings of the study have not met the primary endpoint in this setting, we remain confident in the clinical efficacy of cabozantinib alone and in combination with another treatment in existing indications in difficult-to-treat tu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom